RADARMISSION Ltd™ is an eye tracking-based company founded by Dr. Ioannis Aslanides, MD, PhD, F.R.C.Ophth, MBA who is the Medical Director of Emmetropia Eye Institute, one of the top eye-surgery centers in Greece.
It specializes in applications of eye tracking technology, with a special focus on dyslexia and reading disabilities.
It has pioneered eye tracking research in South Eastern Europe and holds multiple patents for both eye tracking hardware and medical software.
As a leader in its field, it has conducted several research studies and trials in the field of learning difficulties and dyslexia over the last 10 years.
Its current research partners include, among others, Harvard University, USA and Cardiff Metropolitan University, UK.
The company routinely organizes events in Europe raising awareness for dyslexia and learning difficulties and promoting a more informed stance against these disorders.
What is RADAR (Rapid Assessment for Dyslexia & Abnormalities in Reading)
Building on over 30 years of experience in ophthalmology and eye tracking tech, RADARMISSION has developed the RADAR Method, an easy, fast, objective, completely non-invasive and cost-effective screening for reading difficulties, with special focus on dyslexia.
RADAR, which has been developed over the last decade by a multidisciplinary team of scientists is able – in just a few minutes- to quantify the reading process and give us the exact points of difficulty. The RADAR Method is appropriate for all ages and for anyone who wants to know more about his/hers reading fluency.
RADAR uses proprietary, patented software in combination with a commercial, state of the art, eye tracker to asses an individual’s reading capabilities. The whole process takes less than 15 minutes and for the first time an objective and non-invasive assessment for screening dyslexia can be done using silent reading tracked in real time.
All children are entitled, at least once in their life, to have a RADAR exam. By having a negative RADAR test, then you have a 99.3% probability of being non-dyslexic. [Smyrnakis et al. (2017)]
Our journey began in 2007 and continues with the same passion and success until today
Our company, Optotech Ltd. is funded and becomes the first eye tracking company in Greece.
Our journey begins
Eye tracking application in reading.
First, small scale, research with dyslexic students
Dr. Ioannis Aslanides, driven by a family incident, decides to start a project about digitalizing dyslexia and reading difficulties using eye tracking tech.
First publication on DYSLEXIA for dyslexia
We publish our first paper on peer-reviewed journal DYSLEXIA
Research study in a private school
The private school “To Pagrition” allows to our search team to get massive amount of new data samples by assessing the students of the school.
Proudly present our very own eye tracker
In collaboration with Medotics AG, we created our own eye tracker, tailored for eye tracking research in dyslexia and reading.
First, big scale, research study in public schools
Initiate and finalize, in the same year, a big scale research study on students of urban, sub-urban and rural schools of Heraklion, Crete.
Patent granted for RADAR Method
Our team acquires a domestic and an international patent for RADAR Method.
First research study with English dyslexic studies in UK
Our team assesses our first English-speaking population and becomes officially a potential “universal & international screening method for reading difficulties”.
Proud to publish another research study of our team in peer-reviewed journal PLOS ONE
Our multi-disciplinary team publishes the results of our research study on dyslexics and non-dyslexics students.
International collaborations: Harvard & Cardiff MET
We initiated two clinical trials -under IRB- for the English-speaking population of USA and UK, with two renowed universities: Harvard University, with primary investigator Dr. Stelios Smirnakis and with Cardiff Metropolitan University, with primary investigator Dr. Cheryl Ellis.
RADARMISSION Ltd. is funded, in order to make RADAR accessible to a wider audience.